PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Down 66.3% in May

PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) was the recipient of a significant decline in short interest during the month of May. As of May 15th, there was short interest totaling 8,275 shares, a decline of 66.3% from the April 30th total of 24,521 shares. Based on an average trading volume of 23,494 shares, the short-interest ratio is currently 0.4 days. Currently, 0.0% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut PureTech Health from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Institutional Trading of PureTech Health

A hedge fund recently raised its stake in PureTech Health stock. Pentwater Capital Management LP boosted its stake in PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) by 50.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 75,000 shares of the company’s stock after acquiring an additional 25,000 shares during the period. Pentwater Capital Management LP owned 0.31% of PureTech Health worth $1,388,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.04% of the company’s stock.

PureTech Health Price Performance

Shares of NASDAQ:PRTC remained flat at $17.42 during midday trading on Friday. The firm’s 50-day moving average is $16.93 and its 200-day moving average is $17.21. PureTech Health has a 1 year low of $14.50 and a 1 year high of $19.92.

PureTech Health (NASDAQ:PRTC) last announced its earnings results on Friday, April 10th. The company reported ($1.35) EPS for the quarter. The company had revenue of $1.40 million during the quarter.

About PureTech Health

PureTech Health (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.

PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.